In rheumatic heart disease-associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y.
Where this comes from
- Record sourced from PubMed, PMID 36592467.
- Also identified by DOI 10.7326/J22-0102.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Connolly SJ, Karthikeyan G, Ntsekhe M, et al. <b>Rivaroxaban in rheumatic heart disease-associated atrial fibrillation.</b> N Engl J Med. 2022;387:978-88. 36036525.
Medical subject headings
- Rheumatic Heart Disease
- Atrial Fibrillation
- Stroke